PURE Bioscience, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| PURE | KOY.F | CLX | JYOTHYLAB.NS | KNE.V | ALTUV.PA | |
|---|---|---|---|---|---|---|
| Market cap | 9.11M | 2.96B | 11.81B | 73.16B | 7.18M | 10.79M |
| P/E (TTM) | — | 331.7 | 17.6 | 35.3 | — | 79.6 |
| Forward P/E | — | — | 15.8 | 20.8 | — | 4.0 |
| Price/book | -1.3 | 2.5 | -303.4 | 4.8 | -7.0 | 0.3 |
| Dividend yield | — | 1.45% | 5.04% | 1.86% | — | — |
| 1-year change | +16.67% | +38.03% | −6.70% | −39.98% | +33.33% | −53.66% |
| Today | −7.14% | +1.53% | −1.49% | +5.89% | 0.00% | +4.74% |
The closest companies by business and industry (Household & Personal Products). Prices may be delayed up to 15 min.
Latest news
All PURE news ›PURE Bioscience Reports Fiscal 2026 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)-- PURE Bioscience, Inc. (PURE) (OTCQB: PURE) (“PURE,” the “Company,” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the…
PURE Bioscience GAAP EPS of -$0.02, revenue of $2.31M
PURE Bioscience FY results: revenue rose 5.5% YoY to $2.31M, with GAAP EPS of -$0.02. - PURE Bioscience press release (PURE): FY GAAP EPS of -$0.02. More on PURE Bioscience
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- seekingalpha.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.